• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三阴性、基底样和五阴性乳腺癌:更好的生存预测模型。

Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival.

机构信息

Laboratory of Cancer Genomics and Molecular Pathology, Samsung Medical Center, Seoul, Korea.

出版信息

BMC Cancer. 2010 Sep 23;10:507. doi: 10.1186/1471-2407-10-507.

DOI:10.1186/1471-2407-10-507
PMID:20860845
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2957395/
Abstract

BACKGROUND

Triple-negative breast cancers (TNBCs) and basal-like breast cancers (BLBCs) are known as poor outcome subtypes with a lack of targeted therapy. Previous studies have shown conflicting results regarding the difference of prognostic significance between TNBCs and BLBCs. In this study, we aimed to characterize the prognostic features of TNBCs, in view of BLBCs and quintuple-negative breast cancers (QNBC/5NPs).

METHODS

Using tissue microarray-based immunohistochemical analysis, we categorized 951 primary breast cancers into four or five subtypes according to the expression of ER, PR, HER2, and basal markers (CK5/6, EGFR).

RESULTS

The results of this study showed that both TNBCs and BLBCs were associated with high histological and/or nuclear grades. When the TNBCs are divided into two subtypes by the presence of basal markers, the clinicopathologic characteristics of TNBCs were mainly maintained in the BLBCs. The 5-subgrouping was the better prediction model for both disease free and overall survival in breast cancers than the 4-subgrouping. After multivariate analysis of TNBCs, the BLBCs did not have a worse prognosis than the QNBC/5NPs. Interestingly, the patients with BLBCs showed significant adjuvant chemotherapy benefit. In addition, QNBC/5NPs comprised about 6~8% of breast cancers in publicly available breast cancer datasets

CONCLUSION

The QNBC/5NP subtype is a worse prognostic subgroup of TNBCs, especially in higher stage and this result may be related to adjuvant chemotherapy benefit of BLBCs, calling for caution in the identification of subgroups of patients for therapeutic classification.

摘要

背景

三阴性乳腺癌(TNBC)和基底样乳腺癌(BLBC)被认为是预后不良的亚型,缺乏靶向治疗。先前的研究表明,TNBC 和 BLBC 之间的预后意义差异存在矛盾的结果。在这项研究中,我们旨在根据 BLBC 和五阴性乳腺癌(QNBC/5NPs)的特征来描述 TNBC 的预后特征。

方法

使用基于组织微阵列的免疫组织化学分析,我们根据 ER、PR、HER2 和基底标志物(CK5/6、EGFR)的表达将 951 例原发性乳腺癌分为四或五种亚型。

结果

这项研究的结果表明,TNBC 和 BLBC 均与高组织学和/或核分级相关。当 TNBC 通过存在基底标志物分为两种亚型时,TNBC 的临床病理特征主要在 BLBC 中保持。与 4 分组相比,5 分组是乳腺癌无病生存和总生存的更好预测模型。在对 TNBC 进行多变量分析后,BLBC 的预后并不比 QNBC/5NPs 差。有趣的是,BLBC 患者表现出显著的辅助化疗获益。此外,QNBC/5NPs 在公开的乳腺癌数据集约占乳腺癌的 6~8%。

结论

QNBC/5NP 亚型是 TNBC 预后更差的亚组,尤其是在较高的分期中,这一结果可能与 BLBC 的辅助化疗获益有关,因此在为治疗分类确定患者亚组时需要谨慎。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41d0/2957395/dc3016029927/1471-2407-10-507-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41d0/2957395/d4a15a0b9aec/1471-2407-10-507-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41d0/2957395/d9e1f1ba2063/1471-2407-10-507-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41d0/2957395/50f6d8d10bc6/1471-2407-10-507-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41d0/2957395/dc3016029927/1471-2407-10-507-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41d0/2957395/d4a15a0b9aec/1471-2407-10-507-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41d0/2957395/d9e1f1ba2063/1471-2407-10-507-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41d0/2957395/50f6d8d10bc6/1471-2407-10-507-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41d0/2957395/dc3016029927/1471-2407-10-507-4.jpg

相似文献

1
Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival.三阴性、基底样和五阴性乳腺癌:更好的生存预测模型。
BMC Cancer. 2010 Sep 23;10:507. doi: 10.1186/1471-2407-10-507.
2
Triple-Negative Breast Cancer: A Comprehensive Study of Clinical, Histomorphological, and Immunohistochemical Features in Indian Patients.三阴性乳腺癌:印度患者临床、组织形态学及免疫组化特征的综合研究
Int J Surg Pathol. 2017 May;25(3):230-237. doi: 10.1177/1066896916667815. Epub 2016 Sep 9.
3
αB-crystallin is a useful marker for triple negative and basal breast cancers.αB-晶状体蛋白是三阴性和基底型乳腺癌的有用标志物。
Histopathology. 2012 Sep;61(3):378-86. doi: 10.1111/j.1365-2559.2012.04234.x. Epub 2012 Mar 28.
4
Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy.Bcl-2表达在接受蒽环类化疗的非基底型三阴性乳腺癌患者中的预后意义。
Tumour Biol. 2014 Dec;35(12):12255-63. doi: 10.1007/s13277-014-2534-4. Epub 2014 Sep 2.
5
Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers.雄激素受体表达是三阴性乳腺癌的一个有利预后因素。
Hum Pathol. 2018 Oct;80:239-245. doi: 10.1016/j.humpath.2018.06.003. Epub 2018 Jun 11.
6
[Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].[免疫组织化学在基底样乳腺癌预后评估中的作用]
Zhonghua Bing Li Xue Za Zhi. 2009 Jan;38(1):23-8.
7
Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer.Engrailed 1 过表达可作为三阴性乳腺癌的潜在预后标志物。
Cancer Biol Ther. 2018 Apr 3;19(4):335-345. doi: 10.1080/15384047.2018.1423913. Epub 2018 Feb 13.
8
Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.细胞角蛋白5/6、雄激素受体和p53的免疫组化共表达状态作为三阴性乳腺癌辅助化疗的预后因素
Med Mol Morphol. 2016 Mar;49(1):11-21. doi: 10.1007/s00795-015-0109-0. Epub 2015 May 26.
9
Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.三阴性乳腺癌的免疫组化分子分型:分子基础与临床相关性。
Oncologist. 2020 Oct;25(10):e1481-e1491. doi: 10.1634/theoncologist.2019-0982. Epub 2020 Jun 1.
10
Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.在激素受体阴性浸润性乳腺癌中,基底-HER2表型的生存率低于基底样表型。
Hum Pathol. 2008 Feb;39(2):167-74. doi: 10.1016/j.humpath.2007.06.012. Epub 2007 Nov 28.

引用本文的文献

1
Clinical Significance of HER2-low Expression in Triple-negative Breast Cancer: A Retrospective Multicenter Study.人表皮生长因子受体2低表达在三阴性乳腺癌中的临床意义:一项回顾性多中心研究
Cancer Diagn Progn. 2025 Jun 30;5(4):492-498. doi: 10.21873/cdp.10463. eCollection 2025 Jul-Aug.
2
Induction of SUSD2 by STAT3 Activation Is Associated with Tumor Recurrence in HER2-Positive Breast Cancer.STAT3激活诱导SUSD2表达与HER2阳性乳腺癌的肿瘤复发相关。
Cells. 2024 Dec 28;14(1):19. doi: 10.3390/cells14010019.
3
Beyond Triple-Negative: High Prevalence of Quadruple-Negative Breast Cancer in African Americans.

本文引用的文献

1
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.新辅助顺铂在三阴性乳腺癌中的疗效。
J Clin Oncol. 2010 Mar 1;28(7):1145-53. doi: 10.1200/JCO.2009.22.4725. Epub 2010 Jan 25.
2
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.三阴性乳腺癌:区分基底样和非基底样亚型
Clin Cancer Res. 2009 Apr 1;15(7):2302-10. doi: 10.1158/1078-0432.CCR-08-2132. Epub 2009 Mar 24.
3
What is triple-negative breast cancer?什么是三阴性乳腺癌?
超越三阴性:非裔美国人中四阴性乳腺癌的高患病率
Biomedicines. 2024 Jul 9;12(7):1522. doi: 10.3390/biomedicines12071522.
4
c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.c-MET 阳性循环肿瘤细胞和游离 DNA 作为激素受体阳性/HER2 阴性转移性乳腺癌的独立预后因素。
Breast Cancer Res. 2024 Jan 18;26(1):13. doi: 10.1186/s13058-024-01768-y.
5
Discovering the Biological Significance and Therapeutic Potential of miR-29b-3p in Triple-Negative Breast Cancer.揭示 miR-29b-3p 在三阴性乳腺癌中的生物学意义和治疗潜力。
Int J Mol Sci. 2023 Mar 6;24(5):5048. doi: 10.3390/ijms24055048.
6
Tumorigenicity of EGFR- and/or HER2-Positive Breast Cancers Is Mediated by Recruitment of Tumor-Associated Macrophages.表皮生长因子受体(EGFR)和/或人表皮生长因子受体 2(HER2)阳性乳腺癌的致瘤性是通过招募肿瘤相关巨噬细胞来介导的。
Int J Mol Sci. 2023 Jan 11;24(2):1443. doi: 10.3390/ijms24021443.
7
Matrix metalloproteinase 11 (MMP11) in macrophages promotes the migration of HER2-positive breast cancer cells and monocyte recruitment through CCL2-CCR2 signaling.基质金属蛋白酶 11(MMP11)在巨噬细胞中通过 CCL2-CCR2 信号促进 HER2 阳性乳腺癌细胞的迁移和单核细胞募集。
Lab Invest. 2022 Apr;102(4):376-390. doi: 10.1038/s41374-021-00699-y. Epub 2021 Nov 13.
8
Molecular classification predicts survival for breast cancer patients in Vietnam: a single institutional retrospective analysis.分子分类可预测越南乳腺癌患者的生存率:一项单机构回顾性分析。
Int J Clin Exp Pathol. 2021 Mar 1;14(3):322-337. eCollection 2021.
9
High expression of NR1D1 is associated with good prognosis in triple-negative breast cancer patients treated with chemotherapy.NR1D1 高表达与接受化疗的三阴性乳腺癌患者的良好预后相关。
Breast Cancer Res. 2019 Nov 28;21(1):127. doi: 10.1186/s13058-019-1197-x.
10
Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer.亚洲激素受体阳性、HER2阴性早期乳腺癌患者中GenesWell BCT评分与Oncotype DX复发评分用于风险分类的比较
Front Oncol. 2019 Jul 24;9:667. doi: 10.3389/fonc.2019.00667. eCollection 2019.
Eur J Cancer. 2008 Dec;44(18):2799-805. doi: 10.1016/j.ejca.2008.09.034. Epub 2008 Nov 12.
4
The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer.淋巴结阴性乳腺癌中三阴性的临床病理特征及预后意义
BMC Cancer. 2008 Oct 23;8:307. doi: 10.1186/1471-2407-8-307.
5
Basal-like breast cancer: a critical review.基底样乳腺癌:一项批判性综述。
J Clin Oncol. 2008 May 20;26(15):2568-81. doi: 10.1200/JCO.2007.13.1748.
6
How basal are triple-negative breast cancers?三阴性乳腺癌的基础情况如何?
Int J Cancer. 2008 Jul 1;123(1):236-40. doi: 10.1002/ijc.23518.
7
Is triple negative a prognostic factor in breast cancer?三阴性是乳腺癌的一个预后因素吗?
Breast Cancer. 2008;15(4):303-8. doi: 10.1007/s12282-008-0042-3. Epub 2008 Mar 29.
8
Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype.由五种生物标志物定义的基底样乳腺癌比三阴性表型具有更好的预后价值。
Clin Cancer Res. 2008 Mar 1;14(5):1368-76. doi: 10.1158/1078-0432.CCR-07-1658.
9
Are triple-negative and basal-like breast cancer synonymous?三阴性乳腺癌和基底样乳腺癌是同义词吗?
Clin Cancer Res. 2008 Jan 15;14(2):618; author reply 618-9. doi: 10.1158/1078-0432.CCR-07-1943.
10
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients.三阴性乳腺癌:在接受蒽环类辅助治疗的患者中的分子特征及预后影响
Breast Cancer Res Treat. 2008 Sep;111(1):27-44. doi: 10.1007/s10549-007-9756-8. Epub 2007 Oct 6.